应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
COR CENCORA
盘前交易 05-06 05:54:56 EDT
223.95
-0.79
-0.35%
最高
224.86
最低
222.20
成交量
222.20万
今开
223.63
昨收
224.74
日振幅
1.18%
总市值
446.67亿
流通市值
385.93亿
总股本
1.99亿
成交额
4.96亿
换手率
1.29%
流通股本
1.72亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
Baird:维持Cencora(COR.US)评级,由优于大市调整至优于大市评级, 目标价由275.00美元调整至277.00美元。
智通财经 · 05-02
Baird:维持Cencora(COR.US)评级,由优于大市调整至优于大市评级, 目标价由275.00美元调整至277.00美元。
【券商聚焦】申宏万源维持中国财险(02328)“买入”评级 指其业绩短期承压 但COR水平优于可比同业
金吾财讯 · 05-02
【券商聚焦】申宏万源维持中国财险(02328)“买入”评级 指其业绩短期承压 但COR水平优于可比同业
更新版 1-因减肥药短缺,Cencora 收入不及预期
Reuters · 05-01
更新版 1-因减肥药短缺,Cencora 收入不及预期
Cencora 盈利超出预期,原因是昂贵的特药需求强劲
Reuters · 05-01
Cencora 盈利超出预期,原因是昂贵的特药需求强劲
Cencora Inc 预计每股收益3.69美元 - 财报前瞻
Reuters · 04-29
Cencora Inc 预计每股收益3.69美元 - 财报前瞻
BUZZ-卡地纳健康因失去与 UnitedHealth 旗下 OptumRx 的合同而下跌
Reuters · 04-22
BUZZ-卡地纳健康因失去与 UnitedHealth 旗下 OptumRx 的合同而下跌
国泰君安保险24Q1业绩前瞻:利润小幅负增 NBV维持景气 COR略有承压
智通财经 · 04-11
国泰君安保险24Q1业绩前瞻:利润小幅负增 NBV维持景气 COR略有承压
更新版 1-Cencora 在网络安全事件中披露数据泄露事件
Reuters · 02-28
更新版 1-Cencora 在网络安全事件中披露数据泄露事件
沃尔格林博姿第三次减持 Cencora 股份后获利 9.92 亿美元
Reuters · 02-08
沃尔格林博姿第三次减持 Cencora 股份后获利 9.92 亿美元
美国研究综述-空气化工产品公司、Hubspot、麦当劳
Reuters · 02-06
美国研究综述-空气化工产品公司、Hubspot、麦当劳
美国研究综述-空气化工产品公司 , Hubspot 和麦当劳
Reuters · 02-06
美国研究综述-空气化工产品公司 , Hubspot 和麦当劳
美国研究综述-美国电话电报公司、伦诺克斯国际公司、万事达卡
Reuters · 02-01
美国研究综述-美国电话电报公司、伦诺克斯国际公司、万事达卡
Cencora Inc 报告截至 12 月的季度业绩 - 收益摘要
Reuters · 01-31
Cencora Inc 报告截至 12 月的季度业绩 - 收益摘要
由于高价特药需求强劲,Cencora 上调利润展望
Reuters · 01-31
由于高价特药需求强劲,Cencora 上调利润展望
Cencora Inc 预计每股收益2.89美元 - 财报前瞻
Reuters · 01-29
Cencora Inc 预计每股收益2.89美元 - 财报前瞻
美国研究综述-DXC Technology、无花果、枫树熊
Reuters · 01-24
美国研究综述-DXC Technology、无花果、枫树熊
更新版 1-核心业务强劲,沃尔格林第一季度利润超预期,下调股息
Reuters · 01-04
更新版 1-核心业务强劲,沃尔格林第一季度利润超预期,下调股息
加载更多
公司概况
公司名称:
CENCORA
所属市场:
NYSE
上市日期:
--
主营业务:
Cencora, Inc.是全球最大的药品采购和分销服务公司之一,帮助医疗保健供应商以及制药和生物技术制造商改善患者获得产品加强患者护理的机会。该公司提供创新计划和服务,旨在提高药品供应链在人类和动物健康方面的效力和效率。更具体地说,该公司向位于美国和部分全球市场的各种医疗保健提供商提供全面的品牌、专业品牌和非专利药品、非处方医疗产品、家庭医疗用品和设备以及相关服务,包括急性病医院和卫生系统、独立和连锁零售药店、邮购药房、诊所、长期护理和替代地点药房、医师执业、医疗和透析诊所、兽医和其他客户。此外,公司还为医疗保健提供商和制药制造商提供各种相关服务,包括数据分析、结果研究、报销和药物咨询服务、利基优质物流服务、库存管理、药房自动化、药房管理和包装解决方案。
发行价格:
--
{"stockData":{"symbol":"COR","market":"US","secType":"STK","nameCN":"CENCORA","latestPrice":223.95,"timestamp":1714766400000,"preClose":224.74,"halted":0,"volume":2222046,"delay":0,"floatShares":172329000,"shares":199451791,"eps":9.132787,"marketStatus":"盘前交易","marketStatusCode":1,"change":-0.79,"latestTime":"05-06 05:54:56 EDT","open":223.63,"high":224.86,"low":222.2,"amount":496085235.09876,"amplitude":0.011836,"askPrice":293.08,"askSize":100,"bidPrice":114.32,"bidSize":100,"shortable":3,"etf":0,"ttmEps":9.132787,"exchange":"NYSE","tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1715002200000},"adr":0,"listingDate":1285214400000,"adjPreClose":223.95,"adrRate":0,"dividendRate":0.008886,"postHourTrading":{"tag":"盘后","latestPrice":223.95,"preClose":223.95,"latestTime":"19:40 EDT","volume":101811,"amount":22847303.0865,"timestamp":1714779603634},"volumeRatio":1.261383437626035},"requestUrl":"/m/hq/s/COR","defaultTab":"news","newsList":[{"id":"2432676578","title":"Baird:维持Cencora(COR.US)评级,由优于大市调整至优于大市评级, 目标价由275.00美元调整至277.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2432676578","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2432676578?lang=zh_cn&edition=full","pubTime":"2024-05-02 18:56","pubTimestamp":1714647411,"startTime":"0","endTime":"0","summary":"Baird:维持Cencora(COR.US)评级,由优于大市调整至优于大市评级, 目标价由275.00美元调整至277.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405021856558b6cd13d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405021856558b6cd13d&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2432023629","title":"【券商聚焦】申宏万源维持中国财险(02328)“买入”评级 指其业绩短期承压 但COR水平优于可比同业","url":"https://stock-news.laohu8.com/highlight/detail?id=2432023629","media":"金吾财讯","top":-1,"share":"https://www.laohu8.com/m/news/2432023629?lang=zh_cn&edition=full","pubTime":"2024-05-02 17:17","pubTimestamp":1714641438,"startTime":"0","endTime":"0","summary":"金吾财讯 | 申宏万源发研指,中国财险 1Q24公司实现归母净利润58.71亿元人民币,yoy-38.3%;CORyoy+2.2pct至97.9%,表现不及预期,但绝对值优于同业。该行表示,公司持续推进高质量转型,优化业务结构、压降经营成本、提升风险识别能力组合拳有望持续显效,随着监管费用管控政策持续推进,市场有望回归良性竞争,公司经营优势有望持续显现。截至4月29日,公司PB为0.82x,维持“买入”评级。","market":"sh","thumbnail":"https://static.szfiu.com/news/20200915/MGYzMDMzNGFiY2IxZDI0MzU2YTQ4NTEzZTUyODAwMDc0ODA2MTY2.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200915/MGYzMDMzNGFiY2IxZDI0MzU2YTQ4NTEzZTUyODAwMDc0ODA2MTY2.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1936186","is_publish_highlight":false,"gpt_icon":0},{"id":"2432502575","title":"更新版 1-因减肥药短缺,Cencora 收入不及预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2432502575","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2432502575?lang=zh_cn&edition=full","pubTime":"2024-05-01 23:30","pubTimestamp":1714577459,"startTime":"0","endTime":"0","summary":"根据 LSEG 的数据,截至 3 月 31 日的第二季度,Cencora 收入最大的部门--美国医疗保健业务的销售额为 613 亿美元,而分析师预计的销售额为 633.7 亿美元。受治疗癌症和类风湿性关节炎等复杂疾病的昂贵特药需求强劲的推动 ,Cencora 还 上调了 2024 年调整后盈利预期 的下限。经调整后,Cencora 的季度利润为每股 3.80 美元,高于预期的 3.69 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2432520886","title":"Cencora 盈利超出预期,原因是昂贵的特药需求强劲","url":"https://stock-news.laohu8.com/highlight/detail?id=2432520886","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2432520886?lang=zh_cn&edition=full","pubTime":"2024-05-01 19:40","pubTimestamp":1714563628,"startTime":"0","endTime":"0","summary":" 路透5月1日 - 受治疗癌症和类风湿性关节炎等复杂疾病的昂贵特效药需求强劲的推动,Cencora 周三公布的第二季度利润超出华尔街预期。不过,Cencora 公司上个月表示,该公司已经看到仿制药价格通缩的 \"缓和 \"趋势。截至 3 月 31 日的第二季度,Cencora 收入最大的部门--美国医疗保健业务的销售额达到 613 亿美元,同比增长超过 8%。经调整后,Cencora 公布的季度利润为每股 3.80 美元,高于预期的每股 3.69 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2431861280","title":"Cencora Inc 预计每股收益3.69美元 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2431861280","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2431861280?lang=zh_cn&edition=full","pubTime":"2024-04-29 22:05","pubTimestamp":1714399519,"startTime":"0","endTime":"0","summary":"* 根据LSEG的数据,12位分析师的平均预期显示,这家总部位于宾夕法尼亚州康肖霍肯的公司预计将实现11.3%的营收增长,从去年同期的634.6亿美元增至706.53亿美元。 * LSEG 的分析师平均预期 Cencora Inc 每股收益为 3.69 美元。* 华尔街对 Cencora Inc 的 12 个月目标价中位数为 261.50 美元,高于其最新收盘价 240.88 美元。4月29日 - 以前季度业绩。除非另有说明,否则所有数据均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2429203169","title":"BUZZ-卡地纳健康因失去与 UnitedHealth 旗下 OptumRx 的合同而下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2429203169","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2429203169?lang=zh_cn&edition=full","pubTime":"2024-04-22 22:44","pubTimestamp":1713797096,"startTime":"0","endTime":"0","summary":" (更新) 4月22日 - ** 药品分销商卡地纳健康 股价下跌 ~6.2% 跌至 101.52 美元,为 2 月 8 日以来最低点** 该公司表示, ,其与 UnitedHealth 的 OptumRx 部门签订的药品分销合同在 6 月底到期后将不再续约。** 该公司预计将通过赢得新客户和专科药房业务增长来部分抵消失去 OptumRx 合同的影响** Evercore ISI 的分析师估计,失去合同将对卡迪纳尔 2025 年的利润产生 45-50 美分的影响。** OptumRx 是一家药房福利管理公司,在保险公司和制药商之间充当中间人,负责处方药的价格谈判。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2426850052","title":"国泰君安保险24Q1业绩前瞻:利润小幅负增 NBV维持景气 COR略有承压","url":"https://stock-news.laohu8.com/highlight/detail?id=2426850052","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2426850052?lang=zh_cn&edition=full","pubTime":"2024-04-11 14:39","pubTimestamp":1712817579,"startTime":"0","endTime":"0","summary":"投资端看,预计当前长端利率进一步下降空间有限,权益市场呈现企稳回暖态势,推动资产端边际改善,维持行业“增持”。个险银保双轮驱动,预计24Q1NBV较快增长:2024年一季度,个险和银保渠道供需共振预计推动上市险企NBV实现较快增长。财险保费增长承压,预计COR小幅抬升:1)预计2024年一季度财险保费增长承压,主要为头部险企严格执行“报行合一”以及汽车销量下滑影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1101027.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2414633254","title":"更新版 1-Cencora 在网络安全事件中披露数据泄露事件","url":"https://stock-news.laohu8.com/highlight/detail?id=2414633254","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2414633254?lang=zh_cn&edition=full","pubTime":"2024-02-28 07:21","pubTimestamp":1709076108,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供,请见免责声明 )) (添加第 2 段以后的详细信息) 路透社2月27日 - Cencora Inc 周二披露了一起网络安全事件,该药品分销商的信息系统中的数据被盗,其中一些可能包含个人信息。Cencora 在一份监管文件 (link) 中说,该未经授权的活动于 2 月 21 日被发现,公司已立即采取措施加以控制。该公司表示,已在执法部门、网络安全专家和外部顾问的协助下展开调查。Cencora 表示,此次事件未对其运营造成重大影响,其信息系统仍在继续运行。该公司尚未确定该事件是否可能对其财务或运营产生重大影响。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2409178297","title":"沃尔格林博姿第三次减持 Cencora 股份后获利 9.92 亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2409178297","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2409178297?lang=zh_cn&edition=full","pubTime":"2024-02-08 08:30","pubTimestamp":1707352201,"startTime":"0","endTime":"0","summary":" 路透2月8日 - 美国连锁药店沃尔格林博姿 周三表示,它在短短六个多月内第三次减持医药分销商Cencora 的股份,套现约9.92亿美元。沃尔格林表示,它现在持有 Cencora 大约 13% 的普通股,而之前是 15%,出售所得将主要用于偿还债务。沃尔格林表示,此次出售不会影响双方的长期合作关系,沃尔格林的国际首席运营官 Ornella Barra 将继续在 Cencora 董事会任职。沃尔格林在 2023 年 11 月出售了价值约 6.74 亿美元的 Cencora 股票,并在 8 月份的一次出售中赚取了约 18.5 亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2409477656","title":"美国研究综述-空气化工产品公司、Hubspot、麦当劳","url":"https://stock-news.laohu8.com/highlight/detail?id=2409477656","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2409477656?lang=zh_cn&edition=full","pubTime":"2024-02-06 20:33","pubTimestamp":1707222822,"startTime":"0","endTime":"0","summary":" 路透2月6日 - 华尔街证券分析师周二调整了对几家美国上市公司的评级和目标价,其中包括空气化工产品公司、Hubspot 和麦当劳。要闻 * 空气化工产品公司 :摩根大通将目标价从295美元下调至270美元 * Hubspot Inc :杰富瑞将目标价从620美元上调至695美元 * 麦当劳 :BTIG将其目标价从 \"买入 \"下调至 \"中性\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2409482444","title":"美国研究综述-空气化工产品公司 , Hubspot 和麦当劳","url":"https://stock-news.laohu8.com/highlight/detail?id=2409482444","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2409482444?lang=zh_cn&edition=full","pubTime":"2024-02-06 15:31","pubTimestamp":1707204662,"startTime":"0","endTime":"0","summary":" 路透2月6日 - 华尔街证券分析师周二调整了对几家美国上市公司的评级和目标价,其中包括空气化工产品公司、Hubspot 和麦当劳。要闻 * 空气化工产品公司 :摩根大通将目标价从295美元下调至270美元 * Hubspot Inc :杰富瑞将目标价从620美元上调至695美元 * 麦当劳 :BTIG将其目标价从 \"买入 \"下调至 \"中性\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2408550592","title":"美国研究综述-美国电话电报公司、伦诺克斯国际公司、万事达卡","url":"https://stock-news.laohu8.com/highlight/detail?id=2408550592","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2408550592?lang=zh_cn&edition=full","pubTime":"2024-02-01 17:08","pubTimestamp":1706778485,"startTime":"0","endTime":"0","summary":" 路透2月1日 - 华尔街证券分析师周四调整了对几家美国上市公司的评级和目标价,其中包括美国电话电报公司、伦诺克斯国际公司和万事达卡公司。* 8X8 Inc :巴克莱将目标价从2.50美元上调至3美元 * AMD Inc :Northland Capital上调其评级至 \"跑赢大盘\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2407559500","title":"Cencora Inc 报告截至 12 月的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2407559500","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2407559500?lang=zh_cn&edition=full","pubTime":"2024-01-31 22:32","pubTimestamp":1706711574,"startTime":"0","endTime":"0","summary":" * Cencora Inc 公布的截至 12 月的季度调整后每股收益为 3.28 美元,高于去年同期的每股收益 2.71 美元。15 位分析师对该季度的平均预期为每股收益 2.89 美元。华尔街预期为每股收益 2.81 美元至 2.97 美元。* 营收同比增长 15%,达到 722.5 亿美元;分析师预期为 691.7 亿美元。* Cencora Inc 公布的本季度每股收益为 2.98 美元。* 公司报告的季度净收入为 6.015 亿美元。* Cencora Inc 的股价本季度上涨了 7.4%。* 华尔街对 Cencora Inc 的 12 个月目标价中位数为 225.00 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2407532270","title":"由于高价特药需求强劲,Cencora 上调利润展望","url":"https://stock-news.laohu8.com/highlight/detail?id=2407532270","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2407532270?lang=zh_cn&edition=full","pubTime":"2024-01-31 21:14","pubTimestamp":1706706898,"startTime":"0","endTime":"0","summary":"Cencora受益于特药和被称为生物仿制药的复杂生物技术药物廉价版的强劲销售,即使仿制药的价格因激烈竞争而不断下降。Cencora 的收入主要来自其美国医疗保健业务,在截至 12 月 31 日的第一季度,该业务的销售额为 651.8 亿美元,同比增长近 16%。Cencora 现在预测 2024 财年的收入增长率为 10%至 12%,高于之前预测的 7%至 10%。经调整后,Cencora 的每股利润为 3.28 美元,高于 LSEG 预计的每股 2.89 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2407667468","title":"Cencora Inc 预计每股收益2.89美元 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2407667468","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2407667468?lang=zh_cn&edition=full","pubTime":"2024-01-29 21:34","pubTimestamp":1706535278,"startTime":"0","endTime":"0","summary":" * Cencora Inc 将于1月31日公布截至2023年12月31日的财报,预计季度收入将有所增长。* 根据LSEG的数据,9位分析师的平均预期显示,这家总部位于宾夕法尼亚州康肖霍肯的公司的营收将从去年同期的628.5亿美元增至692.33亿美元,增幅为10.2%。* LSEG 分析师对 Cencora Inc 的平均预期为每股收益 2.89 美元。* 华尔街对 Cencora Inc 的 12 个月目标价中值为 225.00 美元,高于其上一次收盘价 217.68 美元。1月29日 - 以前季度业绩。除非另有说明,所有数字均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2405469454","title":"美国研究综述-DXC Technology、无花果、枫树熊","url":"https://stock-news.laohu8.com/highlight/detail?id=2405469454","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2405469454?lang=zh_cn&edition=full","pubTime":"2024-01-24 15:01","pubTimestamp":1706079677,"startTime":"0","endTime":"0","summary":" 路透1月24日 - 华尔街证券分析师周三调整了对几家美国上市公司的评级和目标价,其中包括 DXC Technology、Figs 和 Maplebear。* Maplebear Inc :基准下调至持有 * Vertex Pharmaceuticals Inc :Canaccord Genuity将其评级从持有下调至卖出 * Webster Financial Corp :摩根大通将其评级从中性上调至增持 以下是路透周三报道的美国公司研究行动摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2400536748","title":"更新版 1-核心业务强劲,沃尔格林第一季度利润超预期,下调股息","url":"https://stock-news.laohu8.com/highlight/detail?id=2400536748","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2400536748?lang=zh_cn&edition=full","pubTime":"2024-01-04 20:09","pubTimestamp":1704370148,"startTime":"0","endTime":"0","summary":" 路透1月4日 - 沃尔格林博姿联盟 周四公布第一季度利润好于预期,原因是其药房业务强劲,该公司削减了季度股息,试图节省现金。沃尔格林表示,将把股息支付额削减 48%,降至每股 25 美分。沃尔格林一直在将重点转向综合医疗服务,关闭不盈利的门店并裁员,因为该公司正努力应对来自竞争对手的竞争、COVID 疫苗和测试销售额的大幅下降,以及通胀疲软的消费者可支配支出的减少。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cencora.com","stockEarnings":[{"period":"1week","weight":-0.0703},{"period":"1month","weight":-0.0889},{"period":"3month","weight":-0.047},{"period":"6month","weight":0.1475},{"period":"1year","weight":0.3443},{"period":"ytd","weight":0.0904}],"compareEarnings":[{"period":"1week","weight":0.006},{"period":"1month","weight":-0.0156},{"period":"3month","weight":0.0343},{"period":"6month","weight":0.1762},{"period":"1year","weight":0.262},{"period":"ytd","weight":0.0757}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Cencora, Inc.是全球最大的药品采购和分销服务公司之一,帮助医疗保健供应商以及制药和生物技术制造商改善患者获得产品加强患者护理的机会。该公司提供创新计划和服务,旨在提高药品供应链在人类和动物健康方面的效力和效率。更具体地说,该公司向位于美国和部分全球市场的各种医疗保健提供商提供全面的品牌、专业品牌和非专利药品、非处方医疗产品、家庭医疗用品和设备以及相关服务,包括急性病医院和卫生系统、独立和连锁零售药店、邮购药房、诊所、长期护理和替代地点药房、医师执业、医疗和透析诊所、兽医和其他客户。此外,公司还为医疗保健提供商和制药制造商提供各种相关服务,包括数据分析、结果研究、报销和药物咨询服务、利基优质物流服务、库存管理、药房自动化、药房管理和包装解决方案。","yearOnYearQuotes":[{"month":1,"riseRate":0.785714,"avgChangeRate":0.046624},{"month":2,"riseRate":0.571429,"avgChangeRate":-0.002446},{"month":3,"riseRate":0.571429,"avgChangeRate":0.006015},{"month":4,"riseRate":0.571429,"avgChangeRate":0.015087},{"month":5,"riseRate":0.642857,"avgChangeRate":0.024823},{"month":6,"riseRate":0.535714,"avgChangeRate":0.030328},{"month":7,"riseRate":0.571429,"avgChangeRate":0.013124},{"month":8,"riseRate":0.571429,"avgChangeRate":-0.01131},{"month":9,"riseRate":0.535714,"avgChangeRate":0.02609},{"month":10,"riseRate":0.535714,"avgChangeRate":-0.010036},{"month":11,"riseRate":0.678571,"avgChangeRate":0.028165},{"month":12,"riseRate":0.571429,"avgChangeRate":0.021519}],"exchange":"NYSE","name":"CENCORA","nameEN":"Cencora Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CENCORA(COR)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供CENCORA(COR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"CENCORA,COR,CENCORA股票,CENCORA股票老虎,CENCORA股票老虎国际,CENCORA行情,CENCORA股票行情,CENCORA股价,CENCORA股市,CENCORA股票价格,CENCORA股票交易,CENCORA股票购买,CENCORA股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CENCORA(COR)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供CENCORA(COR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}